SFS
TTNP

Sowell Financial Services’s Titan Pharmaceuticals TTNP Stock Holding History

Sowell Financial Services’s Portfolio TTNP Stock Details TTNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1
Closed – – 2552
2021
Q1 		$0 Hold
1
– – ﹤0.01% 3300
2020
Q4 		$0 Hold
1
– – ﹤0.01% 2858
2020
Q3 		$0 Hold
1
– – ﹤0.01% 2708
2020
Q2 		$0 Hold
1
– – ﹤0.01% 2664
2020
Q1 		$0 Hold
1
– – ﹤0.01% 2689
2019
Q4 		$0 Hold
1
– – ﹤0.01% 2659
2019
Q3 		$0 Buy
+1
New +$451 ﹤0.01% 2461

Other funds holding TTNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
ASN
Advisory Services Network Atlanta, Georgia $8.83B AUM 38.5% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Sowell Financial Services's TTNP Position: Q2 2021 in Review

Sowell Financial Services sold out of Titan Pharmaceuticals (TTNP) in Q2 2021, closing a stake of 1 share.

Sowell Financial Services first reported a position in TTNP in Q3 2019 and held it in 7 quarters. The position peaked at $0 in Q1 2021. 16 funds tracked by Wall St. Rank hold TTNP as of Q2 2021.

  • Sowell Financial Services reported no remaining Titan Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Sowell Financial Services sold 1 Titan Pharmaceuticals share in Q2 2021.
  • Sowell Financial Services first reported a position in Titan Pharmaceuticals in Q3 2019 and held it in 7 quarters.
  • Sowell Financial Services's Titan Pharmaceuticals position peaked at $0 in Q1 2021.
  • 16 funds tracked by Wall St. Rank held Titan Pharmaceuticals as of Q2 2021.

Based on Sowell Financial Services's 13F filing for Q2 2021, filed 5 Aug 2021.